Pfizer has entered into a definitive merger agreement to acquire Hospira, a leading provider of injectable drugs and infusion technologies, as well as biosimilars, for a total value of approximately $17 billion. The global market value for both generic sterile injectables and biosimilars is expected to grow, estimated to be $70 billion and $20 billion in 2020, respectively. The boards of both companies have unanimously approved the merger. The transaction, subject to customary closing conditions...